Contagion Editorial Team

Rising tick-borne illnesses due to warmer winters, strong hepatitis E vaccine efficacy during an outbreak, emerging fungal threats and resistance, and more.

The University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) announced its initiative that will look to ensure reliable vaccine data and information is available to the public and medical community.

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Development of a monoclonal antibody targeting mucormycosis, WHO’s call for improved fungal diagnostics and therapies, Bayesian dosing to optimize antimicrobial therapy, and more.

This week, the FDA approved two new drugs, gepotidacin for treating uUTIs in females aged 12 and older, and Tesamorelin F8 for managing excess abdominal fat in adults with HIV-associated lipodystrophy.

The department is set to lay off 10,000 full-time employees, and with combined efforts, expects the reduction to be a total downsizing of 20,000 employees.

Emblaveo for multidrug-resistant infections, advancing RNA therapies and new vaccine options, Vaxart's oral norovirus vaccine, and synthetic gel for ABSSSI, and more.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

This week, five all-oral TB regimens showed efficacy, fungal biofilm diseases remain challenging, over 2 million pastries were recalled due to contamination, and more.

The approval is based on positive phase 3 clinical trial results, offering an effective option for travelers and others at risk of chikungunya, the mosquito-borne illness.

The new version of its molecular test targets the causes of gastroenteritis.

This week, a study on children with invasive candidiasis showed that switching treatment was just as effective, AI is being explored as a tool to combat AMR, and more.

This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.

Cabotegravir (Vocabria) + rilpivirine (Rekambys) is the first and only complete long-acting injectable regimen for the treatment of HIV.

The company said its oral therapy, S-337395, achieved a 88.94% reduction in viral load.

The fully cooked frozen product was not recalled because the product can no longer be purchased. This does apply to consumers who have the product at home.

Nature Medicine published additional data on Vedanta Biosciences’ Clostridioides difficile investigational therapy, VE303, from its phase 2 trial.

The federal agency approved safety labeling changes to the prescribing information for Abrysvo (Pfizer) and Arexvy (GSK) RSV vaccines for seniors after data from clinical trials, reports to the Vaccine Adverse Event Reporting System (VAERS), and a postmarketing study.

From foodborne illness outbreaks to waterborne diseases and beyond, this year saw developments in the gastrointestinal infection space.

This week, concerns over mutated avian flu in a Louisiana patient, the potential of ibuzatrelvir for COVID-19 treatment, a comparison of ceftolozane-tazobactam and ceftazidime-avibactam for pneumonia treatment, and more.

Here are some of the bigger stories on this topic from this year.

A lot of Systane Lubricant Eye Drops Ultra PF has been voluntarily recalled by the manufacturer.

As the year is ending, here are some of the bigger stories Contagion covered on this topic.

As 2024 winds to a close, take a look back on some of the biggest stories Contagion was following around respiratory infections.

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

The ongoing outbreak in the Democratic Republic of Congo is affecting mostly very young children, and has investigators searching for answers.

Here is a recap of the latest happenings during C diff awareness month.

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.

The clinical stage company, Recursion, dosed its first participant using a novel therapy that is not an antimicrobial.